Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study

Objective: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies. Design: Baseline data from 17 852 subjects enrolled in DAD, a prospective multinational cohort study initiated in 1999. Methods: Cross-sectional analyses of CVD risk factors at baseline. The data collected includes data on demographic variables, cigarette smoking, diabetes mellitus, hypertension, dyslipidaemia, body mass index, stage of HIV infection, antiretroviral therapy. Results: Almost 25% of the study population were at an age where there is an appreciable risk of CVD, with those receiving a protease inhibitor (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI) tending to be older. 1.4% had a previous history of CVD and 51.5% were cigarette smokers. Increased prevalence of elevated total cholesterol (⩾ 6.2 mmol/l) was observed among subjects receiving an NNRTI but no PI [odds ratio (OR), 1.79; 95% confidence interval (CI), 1.45–2.22], PI but no NNRTI (OR, 2.35; 95% CI, 1.92–2.87), or NNRTI + PI (OR, 5.48; 95% CI, 4.34–6.91) compared to the prevalence among antiretroviral therapy (ART)-naive subjects. Subjects who have discontinued ART as well as subjects receiving nucleoside reverse transcriptase inhibitors had similar cholesterol levels to treatment-naive subjects. Higher CD4 cell count, lower plasma HIV RNA levels, clinical signs of lipodystrophy, longer exposure times to NNRTI and PI, and older age were all also associated with elevated total cholesterol level. Conclusion: HIV-infected persons exhibit multiple known risk factors for CVD. Of specific concern is the fact that use of the NNRTI and PI drug classes (alone and especially in combination), particularly among older subjects with normalized CD4 cell counts and suppressed HIV replication, was associated with a lipid profile known to increase the risk of coronary heart disease.

[1]  O. Kirk,et al.  Modelling the 3‐year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) study , 2003, HIV medicine.

[2]  O. Kirk,et al.  Lipid profiles on therapy with PI: The D:A:D (Data collection on adverse events of anti-HIV drugs) study , 2002 .

[3]  S. Sidney,et al.  Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV‐1 Infection? , 2002, Journal of acquired immune deficiency syndromes.

[4]  C. Moore,et al.  Rates of combination antiretroviral treatment change in Australia, 1997–2000 , 2002 .

[5]  M. Moroni,et al.  Body Habitus Changes and Metabolic Alterations in Protease Inhibitor‐Naive HIV‐1‐Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors , 2002, Journal of acquired immune deficiency syndromes.

[6]  O. Kirk,et al.  Distinguishable Lipid Profiles between PI and NNRTI Therapy may carry different risk of cariovascular disease (CVD) , 2002 .

[7]  Bg Gazzard and.  British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.

[8]  B Clotet,et al.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile , 2001, AIDS.

[9]  M. Dubé,et al.  Elevated blood pressure in subjects with lipodystrophy , 2001, AIDS.

[10]  P. Reiss,et al.  [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. , 2001, Nederlands tijdschrift voor geneeskunde.

[11]  Nina Singh,et al.  Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy , 2001, International journal of STD & AIDS.

[12]  P. Cadrobbi,et al.  Indinavir and systemic hypertension. , 2001, AIDS.

[13]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[14]  R. Weber,et al.  Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. , 2000, AIDS.

[15]  J. Mallolas,et al.  Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[17]  P. Francioli,et al.  Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. , 2000, Schweizerische medizinische Wochenschrift.

[18]  S. Hammer,et al.  Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. , 2000, Archives of internal medicine.

[19]  H Jacqmin-Gadda,et al.  Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment , 2000, AIDS.

[20]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[21]  H. Jacqmin-Gadda,et al.  Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). , 2000, Journal of acquired immune deficiency syndromes.

[22]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[23]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[24]  O. Rouvière,et al.  Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study , 2000, AIDS.

[25]  N. Clumeck,et al.  Cerebral Toxoplasmosis over the last 10 years in a 2394 patient cohort in Brussels , 2000 .

[26]  B. Gazzard,et al.  Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. , 2000, Journal of acquired immune deficiency syndromes.

[27]  C. Grunfeld,et al.  Fat distribution and metabolic changes in patients with HIV infection. , 1999, AIDS.

[28]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[29]  L. Bricker,et al.  Myocardial Infarction in HIV-Infected Men Receiving Protease Inhibitors , 1999, Annals of Internal Medicine.

[30]  L. Poston,et al.  British Hypertension Society guidelines for hypertension management 1999: summary , 1999, BMJ.

[31]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[32]  H. Schmidt,et al.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. , 1999, AIDS.

[33]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[34]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[35]  D. Grafnetter,et al.  Quality assessment of total cholesterol measurements in the WHO MONICA Project , 1999 .

[36]  M. Karmochkine,et al.  Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. , 1998, AIDS.

[37]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[38]  C. Pradier,et al.  Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T‐cell count? , 1998, AIDS.

[39]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[40]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[41]  D. Vittecoq,et al.  Vascular complications associated with use of HIV protease inhibitors , 1998, The Lancet.

[42]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[43]  K. Henry,et al.  Severe premature coronary artery disease with protease inhibitors , 1998, The Lancet.

[44]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[45]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[46]  J. Nielsen,et al.  Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[47]  C. Packard,et al.  Point: status of lipid and lipoprotein standardization. , 1997, Clinical chemistry.

[48]  C. Sergeant,et al.  Plasma lipids in HIV‐infected patients: a prospective study in 95 patients , 1994, European journal of clinical investigation.

[49]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[50]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[51]  J. Wang,et al.  Hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[52]  J. Ordovás,et al.  Postprandial plasma lipoprotein changes in human subjects of different ages. , 1988, Journal of lipid research.

[53]  S. J. Smith,et al.  Standardization of lipid, lipoprotein, and apolipoprotein measurements. , 1988, Clinical chemistry.

[54]  HELEN B. HUBERT,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[55]  A. Dyer,et al.  Epidemiologic findings on the relationship of time of day and time since last meal to five clinical variables: serum cholesterol, hematocrit, systolic and diastolic blood pressure, and heart rate. , 1978, Preventive medicine.